Home / Intelligence / White Papers / Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be best leveraged across the life sciences industry to improve patient outcomes.
Our goal was to gather HEOR thought leaders across the industry including representatives from pharmaceutical, medical devices/diagnostics and academia to weigh in on these topics. The objective was to gather perspectives on an extensive range of topics including the future of HEOR as a field, its ability to drive decision-making, its central role across the entire lifecycle and evidence generation overall—both in the U.S. and abroad. Our discussions centered around how HEOR and evidence generation will play a role in the evolution of the life sciences industry, from pharmaceuticals and biotechnology to devices and diagnostics. Most importantly, we discussed outcomes overall–including the individual and societal levels, as well as public health. Across the interviews, the discussion focused on the growing importance of Real-World Data (RWD) and specifically on data on social determinants of health (SDOH) and patient-reported outcomes (PROs).
In the paper that follows, we share with you our findings, the methods we used and most importantly, the great perspectives we heard. In addition, we offer (often in the words of the respondents themselves) insights into the current and future field of HEOR and evidence generation overall, articulating why this is an important function for any aspiring life sciences company. Through this initiative, we begin to illuminate how the healthcare industry can best utilize the HEOR specialty to unlock the potential value in a therapy or technology via rigorous analyses and well-articulated value stories.
Complete the form below to access the full whitepaper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Measuring the Impact of Field Medical Affairs
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes. When […]
Read More
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More